Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity.
about
Parenteral adjuvant activities of Escherichia coli heat-labile toxin and its B subunit for immunization of mice against gastric Helicobacter pylori infectionCholera toxin: a paradigm of a multifunctional proteinRoles and relevance of mast cells in infection and vaccinationEscherichia coli heat-labile detoxified enterotoxin modulates dendritic cell function and attenuates allergic airway inflammationSide-by-side comparison of gene-based smallpox vaccine with MVA in nonhuman primatesRefocusing of B-cell responses following a single amino acid substitution in an antigenImmunology of Gut Mucosal VaccinesAttenuated Shigella flexneri 2a vaccine strain CVD 1204 expressing colonization factor antigen I and mutant heat-labile enterotoxin of enterotoxigenic Escherichia coli.Antipeptide antibody responses following intranasal immunization: effectiveness of mucosal adjuvants.Characterization of human immunodeficiency virus Gag-specific gamma interferon-expressing cells following protective mucosal immunization with alphavirus replicon particles.Protective mucosal immunity to ocular herpes simplex virus type 1 infection in mice by using Escherichia coli heat-labile enterotoxin B subunit as an adjuvant.The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a protective antigen and a major virulence factor.The immune responses to bacterial antigens encountered in vivo at mucosal surfaces.Biological and biochemical characterization of variant A subunits of cholera toxin constructed by site-directed mutagenesis.Oral administration of influenza vaccine in combination with the adjuvants LT-K63 and LT-R72 induces potent immune responses comparable to or stronger than traditional intramuscular immunizationZonula occludens toxin is a powerful mucosal adjuvant for intranasally delivered antigens.Intranasal immunization of mice with influenza vaccine in combination with the adjuvant LT-R72 induces potent mucosal and serum immunity which is stronger than that with traditional intramuscular immunization.Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants.Local and systemic neutralizing antibody responses induced by intranasal immunization with the nontoxic binding domain of toxin A from Clostridium difficile.Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of Escherichia coli heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections.Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells.Recombinant antigen-enterotoxin A2/B chimeric mucosal immunogens differentially enhance antibody responses and B7-dependent costimulation of CD4(+) T cells.Intranasal immunization with SAG1 and nontoxic mutant heat-labile enterotoxins protects mice against Toxoplasma gondii.Escherichia coli heat-labile enterotoxin B subunit is a more potent mucosal adjuvant than its vlosely related homologue, the B subunit of cholera toxin.Intimin-specific immune responses prevent bacterial colonization by the attaching-effacing pathogen Citrobacter rodentiumThe LTR72 mutant of heat-labile enterotoxin of Escherichia coli enhances the ability of peptide antigens to elicit CD4(+) T cells and secrete gamma interferon after coapplication onto bare skinEnhancement of protective efficacy following intranasal immunization with vaccine plus a nontoxic LTK63 mutant delivered with nanoparticlesGenetically manipulated bacterial toxin as a new generation mucosal adjuvant.Immunomodulation using bacterial enterotoxins.Rectal immunization with rotavirus virus-like particles induces systemic and mucosal humoral immune responses and protects mice against rotavirus infection.T-cell-mediated mucosal immunity in the absence of antibody: lessons from Helicobacter pylori infection.Functional diversity of heat-labile toxins (LT) produced by enterotoxigenic Escherichia coli: differential enzymatic and immunological activities of LT1 (hLT) AND LT4 (pLT)Mucosal vaccination against serogroup B meningococci: induction of bactericidal antibodies and cellular immunity following intranasal immunization with NadA of Neisseria meningitidis and mutants of Escherichia coli heat-labile enterotoxin.Pneumococcal polysaccharide abrogates conjugate-induced germinal center reaction and depletes antibody secreting cell pool, causing hyporesponsiveness.Adjuvant activity of the catalytic A1 domain of cholera toxin for retroviral antigens delivered by GeneGunEvaluation of the LTK63 adjuvant effect on cellular immune responses to measles virus nucleoprotein.Use of inactivated Escherichia coli enterotoxins to enhance respiratory mucosal adjuvanticity during vaccination in swine.A second generation of double mutant cholera toxin adjuvants: enhanced immunity without intracellular trafficking.The Divergent CD8+ T Cell Adjuvant Properties of LT-IIb and LT-IIc, Two Type II Heat-Labile Enterotoxins, Are Conferred by Their Ganglioside-Binding B Subunits.Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines.
P2860
Q24548763-B3A76D58-458A-4E39-B396-B934146511E3Q24598726-888C5ED5-CC46-4364-A127-8CEDABFC285FQ26777264-7815B725-7C0C-468A-8EFB-6ACC734C71F2Q27318601-6A5A6868-F8F2-4B87-83D4-380BAD1D11C9Q27325586-908521DB-B655-4432-A0AB-AD25DBAC65BFQ28367028-7FBE0E12-D9D4-4FA5-BAC1-42B36A9BEB3EQ28972559-DEED0441-A1FB-4B1F-A8B8-F840D461482BQ33597022-46178B4C-F484-44D4-ACCB-94D3D2DC0C27Q33597488-D5D96DCB-C61C-46C6-B079-70C0FCE6FACEQ33788861-0B5155BE-0BCB-482A-B05B-0A6F901C02A9Q33837275-543BBF4B-CE6A-4C91-8E02-041AB47669E2Q33900152-7F10EE71-BB26-451B-9F17-11BAC617F38AQ33955531-05CA5CC3-B1D9-4689-90C6-D30A0D214F5BQ33996430-0F2D79B4-13F8-47F6-9F46-04B29190FF54Q33999182-A61B4F75-CFFC-4CB6-9E01-950AB07FE141Q34000623-D1B357F8-3DB0-4CDF-979C-0E57763CE0B5Q34001562-27243788-3031-4332-8B0E-EFAFA8CE9EA4Q34001658-C975749D-E9D8-4F47-93EB-FA32235DC206Q34002040-73A976C0-F3C4-4E58-B204-B2FC696B57B2Q34002470-320FFCA2-A626-46F6-AE98-D4A96C5B1B01Q34002672-C64932AF-E311-4FC3-8C1B-6220D6EF92FBQ34005585-6656AA2E-A3CA-4E96-BDB7-EA8987609DE5Q34006385-A79BF516-A5E2-4C72-9C4A-53691220393AQ34007453-80F444A1-6DFB-45A5-99C7-385ABB8BCF00Q34008961-118AB3E1-2C59-40C4-9925-01166100A4AAQ34123358-10BA675B-79CA-403A-AE84-4A41B3948955Q34130228-A112FF92-5A48-43BB-8C60-1D513C43E80AQ34184890-2065966E-D1E8-4FA1-B2C5-D04D5FE02609Q34184898-D3054004-0ACD-4334-87F7-7A13BDBF8BA1Q34353344-7918DDD3-495A-4876-97D9-DF9DE8DE924EQ34380115-71721997-623B-4A57-BB84-1FBC23A6B130Q34568384-3DAB4885-4D21-4BF0-A2ED-B9A93A486277Q34761746-3F650A07-D57A-4053-A914-DCB886215BD8Q34998490-CA9712CB-C68A-462A-8337-3BF3D9A969C8Q35066456-B9C78021-E68B-4F29-A639-221F2EDA3334Q35171910-EC4AFBC9-FC65-4F28-8AB4-A02B419EF608Q35530231-DB26DAE8-2DFB-4BD3-AF4D-EFAE1EFC6519Q35747402-064072A4-DF05-4813-9713-BD0B77C8E0A8Q35840727-0A7EEB2C-C5B2-40C7-8BA4-55A5F8BB5674Q35953762-6CAE0217-46C3-4980-9692-3202081D0B24
P2860
Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Mucosal adjuvanticity and immu ...... P-ribosyltransferase activity.
@en
type
label
Mucosal adjuvanticity and immu ...... P-ribosyltransferase activity.
@en
prefLabel
Mucosal adjuvanticity and immu ...... P-ribosyltransferase activity.
@en
P2093
P2860
P356
P1476
Mucosal adjuvanticity and immu ...... P-ribosyltransferase activity.
@en
P2093
G Del Giudice
M M Giuliani
R Rappuoli
V Giannelli
P2860
P304
P356
10.1084/JEM.187.7.1123
P407
P577
1998-04-01T00:00:00Z